Latest News

Latest News

Clinical Trials Roundup | 05 June 2026

Clinical Trials Roundup | 05 June 2026

Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...

read more
The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Sourcing Channel Moved East

The Sourcing Channel Moved East

A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

read more
Parkinson’s Research Field is Approaching a Pivotal Moment

Parkinson’s Research Field is Approaching a Pivotal Moment

Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...

read more
The Emerging Health Tech Driving Globalised Healthcare

The Emerging Health Tech Driving Globalised Healthcare

Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...

read more
PDUFA Date Explained: FDA Drug Approval Deadlines

PDUFA Date Explained: FDA Drug Approval Deadlines

Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...

read more
Weekly News Roundup | 1 June 2026

Weekly News Roundup | 1 June 2026

Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...

read more
The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more
The Sourcing Channel Moved East

The Sourcing Channel Moved East

A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

read more
Parkinson’s Research Field is Approaching a Pivotal Moment

Parkinson’s Research Field is Approaching a Pivotal Moment

Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...

read more
The Emerging Health Tech Driving Globalised Healthcare

The Emerging Health Tech Driving Globalised Healthcare

Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...

read more
PDUFA Date Explained: FDA Drug Approval Deadlines

PDUFA Date Explained: FDA Drug Approval Deadlines

Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...

read more
Weekly News Roundup | 1 June 2026

Weekly News Roundup | 1 June 2026

Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...

read more
The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more

Featured Articles

Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Life Science Daily News: Join the Community

A Community-Driven Hub for Life Sciences News and Discovery In an era of rapid scientific progress and near-constant breakthroughs, having a reliable, inclusive platform to share and explore life-sciences news is more important than ever. Life Science Daily News...
Fezolinetant menopause treatment is making headlines—but is it safe? A doctor explains the risks women must know.

I’m a Menopause Doctor – Here’s the Real Problem with Fezolinetant

With news of a HRT alternative for women struggling with hot flushes now available on the NHS, Dr Louise Newson explains why when it comes to Fezolinetant, women need to proceed with caution. UK medicines regulator NICE reported that they're in the final stages of...

Welcome to Life Science Daily News

Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...

Further News

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries: Why Vascular Aging Is the Heart Health Crisis We're Missing We are living in an era of extraordinary innovation in heart health. Precision diagnostics. AI-guided therapies. Wearables that track everything from rhythm to recovery. And...

read more
Kailera Therapeutics IPO: A $625M Signal for Biotech

Kailera Therapeutics IPO: A $625M Signal for Biotech

When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

read more
Climate-Sensitive Maternal Mental Health Screening

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more
Weekly News Roundup | 25 May 2026

Weekly News Roundup | 25 May 2026

Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...

read more

Further News

AI Will Not Solve Healthcare Inequality. But it Could Lower the Barriers

There’s a lot of discussion right now around AI in healthcare, but most of it feels disconnected from how clinical research actually works day-to-day. A lot of the conversation is centered around automation, replacing people, chatbots, and efficiency. Some of that...

How AI Infrastructure Accelerates the Next Phase of Healthcare Innovation

Artificial intelligence is beginning to reshape healthcare in ways that would have seemed unrealistic just a decade ago. Hospitals are experimenting with tools that can analyze medical images in seconds, help clinicians monitor patients remotely, and even assist with...

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries: Why Vascular Aging Is the Heart Health Crisis We're Missing We are living in an era of extraordinary innovation in heart health. Precision diagnostics. AI-guided therapies. Wearables that track everything from rhythm to recovery. And...

Kailera Therapeutics IPO: A $625M Signal for Biotech

When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

CRISPR-GPT: Stanford’s AI Tool That Automates Gene Editing

A team of researchers from Stanford University School of Medicine, Princeton University, the University of California Berkeley, and Google DeepMind has developed CRISPR-GPT, an AI gene editing system designed to automate and dramatically simplify CRISPR-based gene...

Modernizing Safety: The Predictive Power of In Vitro Toxicology

As global regulators and scientific communities continue to push for more predictive, human-relevant, and ethical approaches to safety testing, in vitro toxicology has emerged as a critical component of modern drug development. Once seen primarily as an early...

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

Turning AI Skeptics into AI Advocates Through High-Integrity Data

For years, biopharma has accumulated vast volumes of data. Now, as the industry races toward an AI-driven future, that data must become a true strategic asset. Recent research shows that while 95% of biopharma companies are actively pursuing AI initiatives in...

Burnout is Not a Personal Failure. It is Often a System Design Problem

Burnout has long been viewed as a matter of individual resilience. Individuals are advised to meditate, sleep well, optimise morning routines, cut down on screen time, show gratitude, achieve a good work-life balance, or just be better at managing time. While these...

Weekly News Roundup | 25 May 2026

Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...

Fixing the Wrong Problem: How Healthcare Misdiagnoses its Workforce Crisis

The healthcare sector has a burnout problem it keeps trying to solve with the wrong tools. Across Australia and globally, rates of psychological distress, absenteeism and early career exit among healthcare workers have reached levels that can no longer be attributed...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.